WO1998050058A1 - Formation de complexes entre un adn a double brin et un oligomere d'heterocycles - Google Patents

Formation de complexes entre un adn a double brin et un oligomere d'heterocycles Download PDF

Info

Publication number
WO1998050058A1
WO1998050058A1 PCT/US1997/012733 US9712733W WO9850058A1 WO 1998050058 A1 WO1998050058 A1 WO 1998050058A1 US 9712733 W US9712733 W US 9712733W WO 9850058 A1 WO9850058 A1 WO 9850058A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligomer
heterocycles
oligomers
dsdna
cell
Prior art date
Application number
PCT/US1997/012733
Other languages
English (en)
Inventor
Peter Dervan
Joel M. Gottesfeld
Original Assignee
California Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute Of Technology filed Critical California Institute Of Technology
Priority to EP97934244A priority Critical patent/EP0991417A1/fr
Priority to AU37347/97A priority patent/AU747998B2/en
Priority to CA002299455A priority patent/CA2299455A1/fr
Priority to JP54801198A priority patent/JP2002514219A/ja
Publication of WO1998050058A1 publication Critical patent/WO1998050058A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • a 2: 1 complex with dsDNA is formed, with the two chains of the oligomer antiparallel, where G/C pairs have Im Py in juxtaposition, C/G pairs have Py/Im, and T/A pairs have Py/Py in juxtaposition.
  • the heterocycle oligomers are joined by amide carbamyl) groups, where the NH may participate in hydrogen bonding with nitrogen unpaired electrons, particularly of adenine. While the complexes were of substantial interest, the binding affinities for the most part were less than about 10 6 M "1 . Furthermore, the discrimination between a target DNA sequence, and one involving a mismatch was frequently not better than about two-fold. Therefore, for many purposes, the complexes had limited utility.
  • Methods and compositions are provided for selectively producing a complex intracellularly at low concentrations, between dsDNA and an oligomer of organic cyclic groups, wherein at least 60% of the cyclic groups are heterocyclics, and at least 60% of the heterocycles have at least one nitrogen annular member.
  • the heterocycles form complementary pairs, where at least two of the nucleotide pairs are preferentially paired with a specific pair of heterocycles.
  • There are at least three complementary pairs of organic cyclic groups in the complex either as a result of a hairpin turn in a single oligomer, or the complementation between organic cyclic groups of two oligomeric molecules.
  • a small aliphatic amino acid will be interspersed in or divide what would otherwise be a chain of six or more consecutive organic cyclic groups.
  • a terminus may have at least one aliphatic amino acid of from two to six carbon atoms and/or an alkyl chain having a polar group proximal to the linkage of the alkyl chain.
  • Modifications of the oligomers are used to provide for specific properties and are permitted at sites which do not significantly interfere with the oligomers positioning in the minor groove.
  • the compositions are found to be able to enter viable cells and inhibit transcription of genes comprising the target sequence, cleave at particular sites, become covalently bonded at specific sites, direct selected molecules to a target site, as well as perform other activities of interest.
  • the oligomers are combined with cells in culture, in vivo and ex vivo under conditions where the oligomers are transported across the cell membrane to the nucleus, where the oligomers bind to the dsDNA with high affinity. Binding of the oligomers with inhibition of transcription can be used in research, modification of phenotype for change in characteristics of a host, for example, in animal husbandry and breeding, in prophylactic and therapeutic treatment, and the like.
  • FIGURES 1(a) - 1(c) illustrate the nine zinc finger protein TFIIIA with the 5S RNA gene internal control region (ICR).
  • Circles with dots represent lone pairs on N3 of purines and 02 of pyrimidines.
  • Circles containing an H represent the N2 hydrogen of guanine.
  • Figure 2 depicts binding models for (a) 5'-AGTACT-3' in complex with polyamides 1 (match) and 2 (mismatch), and (b) 5'-AGTATT-3' in complex with polyamides 2 (match) and 1 (mismatch).
  • Circles with dots represent lone pairs on N3 of purines and O2 of pyrimidines, and circles containing an H represent the N2 hydrogen of guanine. Putative hydrogen bonds are illustrated by dashed lines.
  • the dark and open circles represent imidazole and pyrrole rings, respectively, the curved line represents ⁇ - aminobutyric acid, and the diamond represents ⁇ -alanine. Single hydrogen bond mismatches are highlighted.
  • the subject invention provides novel oligomers for forming high affinity complexes with dsDNA.
  • the oligomers comprise organic cyclic groups joined together by short linkers, which oligomers fit in the minor groove of dsDNA and form complementary pairs with specific nucleotide base pairs in the dsDNA target sequence.
  • Associated with the organic cyclic compounds are aliphatic amino acids, particularly aliphatic amino acids having a terminal amino group.
  • a terminus will desirably have a polar group, conveniently substituted on an alkyl substituent.
  • compositions are shown to be capable of being transported across cellular membranes to the nucleus, binding to chromosomal DNA, and fulfilling a variety of intracellular functions, including inhibiting transcription.
  • the compositions may be modified to be used in diagnostics, particularly by providing for detectable labels, or may be used in research or therapeutics, to inhibit transcription of target genes.
  • the compositions may be otherwise modified to enhance properties for specific applications, such as transport across cell walls, association with specific cell types, cleaving of nucleic acids at specific sites, change chemical and physical characteristics, and the like.
  • the oligomers of the subject invention will have at least six organic heterocyclic groups, more usually at least seven, and may have eight or more, usually not more than about thirty, more usually not more than about twenty, frequently not more than about 18, organic cyclic groups, wherein at least 60%, preferably at least 80%, and more preferably at least 100% are heterocycles.
  • the heterocycles generally have from one to three, more usually from one to two heteroatoms, where the heteroatoms are nitrogen, oxygen and sulphur, particularly nitrogen.
  • the nitrogen atoms may be substituted, depending upon whether the nitrogen atom is directed toward the floor or surface of the groove or away from the groove. Greater latitude in the nature of the substitution is permitted when the nitrogen atom is directed away from the floor of the groove.
  • the orientation of the oligomer is preferably N to C in association with the 5' to 3' direction of the strand to which it is juxtaposed.
  • the heterocycles may be substituted at positions of the heterocycle which are directed away from the floor of the groove for any purpose.
  • a hydrogen atom may be substituted with a substituent of interest, where the substituent will not result in steric interference with the wall of the minor groove or otherwise create repulsion.
  • the substituents may be widely varied, being heteroatom, hydrocarbyl of from 1 to 30, more usually 1 to 20, carbon atoms, particularly 1 to 10, more particularly 1 to 6 carbon atoms, including aliphatic, alicyclic, aromatic, and combinations thereof, including both aliphatically saturated and unsaturated, having not more than 10% of the carbon atoms participating in aliphatic unsaturation, heterosubstituted hydrocarbyl (as defined previously), having from 1 to 10, usually 1 to 8, more usually 1 to 6, heteroatoms, including aliphatic, alicyclic, aromatic and heterocyclic, and combinations thereof, where the heteroatoms are exemplified by halogen, nitrogen, oxygen, sulfur, phosphorous, metal atoms, boron, arsenic, selenium, rare earths, and the like, wherein functional groups are exemplified by amino, including mono- and disubstituted amino, oxy, including hydroxy and oxyether, thio, including mercapto and
  • the functional groups may be bonded to an annular member or to a substituent bonded to an annular member, e.g. carboxyalkyl, methoxyethyl, methoxymethyl, aminoethyl, dialkylaminopropyl, polyoxyethylene, poly aminoethy lene, etc.
  • substituents e.g. carboxyalkyl, methoxyethyl, methoxymethyl, aminoethyl, dialkylaminopropyl, polyoxyethylene, poly aminoethy lene, etc.
  • annular nitrogen substituents conveniently, they will be substituted with an alkyl group of from 1 to 3 carbon atoms, particularly methyl, and at least one adjacent annular carbon atom unsubstituted.
  • individual substituents will be under 600 Dal, usually under about 300 Dal, and preferably under about 150 Dal and the total for substituents bonded to annular members will be under about 5 kDal, usually under about 2 kDal, more usually under about 1 kDal, there generally being from about 0 to 5, more usually from about 0 to 3 substituents, for other than the alkyl of from 1 to 3 carbon atoms bonded to annular nitrogen.
  • the total carbon atoms for the substituents will not be greater than about 100, usually not greater than about 60, more usually not greater than about 30, with not more than 30 heteroatoms, usually not more than 20 heteroatoms, more usually not more than about 10 heteroatoms.
  • the heterocycles will normally be linked at the 2 position and the 4 or 5 position, particularly the 2 and 4 position for 5 annular member rings.
  • the heterocycles are five to six annular members, particularly five annular members, having from one to three, usually one to two heteroatoms, where two heteroatoms are usually spaced apart by at least one intervening carbon atom.
  • the organic cyclic groups are completely unsaturated and will be referred to as aromatic as that term is understood for organic cyclic compounds of from five to six annular members.
  • Illustrative annular members include pyrrole, imidazole, triazole, furan, thiophene, oxazole, thiazole, pyrazole, cyclopentadiene, pyridine, pyrimidine, triazine, and the like, where as indicated above, NH groups in the rings when substituted are preferably alkylated with an alkyl group of from one to three carbon atoms, particularly methyl.
  • the preferred organic cyclic compounds are five membered rings having from one to two nitrogen atoms, where one of the nitrogen atoms is methylated.
  • the linking groups between the organic cyclic groups will generally have a length of two atoms, wherein at least some of the linking groups will have NH, where the NH may hydrogen bond with an unshared pair of electrons of the nucleotides.
  • the linking chains may be methyleneamino, carbamyl (-CONH-), ethylene, thiocarbamyl, imidinyl, and the like, particularly carbamyl and its heteroanalogs, e.g. thio and imino.
  • aliphatic amino acids are employed, particularly ⁇ -amino aliphatic amino acids, either to provide for hairpin turns to provide complementation between two sequences of heterocycles, to form a cyclic compound where the oligomers are joined at both ends, or to provide for a shift in spacing of the organic cyclic compounds in relation to the target dsDNA.
  • the aliphatic amino acids will have a chain as a core structure of two to six carbon atoms, usually of two to four carbon atoms, desirably having terminal amino groups, particularly glycine, ⁇ - alanine, and ⁇ -aminobutyric acid, being unsubstituted or substituted on carbon and nitrogen, particularly carbon, although for the most part the aliphatic amino acids will be unsubstituted.
  • terminal amino groups particularly glycine, ⁇ - alanine, and ⁇ -aminobutyric acid
  • the carboxyl group will usually be functionalized as an ester or amide, where the alcohol or amino acid may be selected to provide for specific properties or be used to reduce the charge of the carboxyl group.
  • the alcohol and amino groups will generally be from 0 to 6 carbon atoms, usually from 0 to 3 carbon atoms.
  • the longer chain aliphatic amino acid will serve to provide for turns in the molecule and to close the molecule to form a ring.
  • the shorter chain aliphatic amino acids will be employed, both to provide a shift for spacing in relation to the target dsDNA, and to provide enhanced binding by being present proximal to the terminal organic cyclic group.
  • the aliphatic amino acid may be present at one or both ends of the oligomer.
  • glycine and alanine for space-shifting, ⁇ -alanine is preferred. Usually, a consecutive sequence of 6 heterocycles will be avoided.
  • an amino acid particularly ⁇ -alanine
  • an amino acid particularly ⁇ -alanine
  • an amino acid particularly ⁇ -alanine
  • an amino acid particularly ⁇ -alanine
  • the following table indicates the effect of extension of the oligomer heterocycles without introducing an amino acid in the chain.
  • the aliphatic chains of the aliphatic amino acids may serve as sites of substitution, the aliphatic amino acid providing a core structure, there usually being not more than 2, more usually not more than 1 , substituent.
  • substituents that have been described for the heterocycles may also be employed here.
  • the substituted aliphatic amino acid may be used in the synthesis of the oligomer, rather than modifying the amino acid after the oligomer is formed.
  • a functional group may be present on the chain of the substituent, if necessary being appropriately protected during the course of the synthesis, which functional group may then be used for the subsequent modification.
  • such functional group could be selectively used, for synthesis of different oligomers, so as to provide for substitution at that site to produce products having unique properties associated with a particular application.
  • substituent substituted at a site which does not significantly interfere with the binding in the groove e.g. employing a single stereoisomer
  • properties can be imparted to the subject compounds, such as water solubility, lipophilicity, non-covalent binding to a receptor, radioactivity, fluorescence, etc.
  • One or both termini preferably one of the termini, will have a polar group substituted on an alkyl group, where the polar group will generally be from 2 to 6, more usually 2 to 4, carbon atoms from the linkage to the remaining molecule.
  • the polar group may be charged or uncharged, where the charge may be a result of protonation under the conditions of use.
  • groups capable of hydrogen bonding are preferred, such as amino, particularly tertiary-amino, hydroxyl, mercapto, and the like.
  • amino more particularly alkylated amino, where the alkyl groups are of from 1 to 6, usually 1 to 3, more usually 1, carbon atom, and at a pH less than about eight, the amino group is positively charged, and can hydrogen bond with the dsDNA.
  • the amino group is positively charged, and can hydrogen bond with the dsDNA.
  • two positively charged polar groups will not be employed on the oligomers, where the positively charged polar groups will be in juxtaposition when complexed with the dsDNA. It is found that the presence of the two positively charged polar groups in proximity tends to reduce the binding affinity of the oligomer.
  • an isotopic oligomer where one can analyze for its presence, using scintillation counters for radioactive elements, nmr for atoms having a magnetic moment, and the like.
  • a radioactive label may be employed, such as tritium, 14 C, 125 I, or the like.
  • the radiolabel may be a substituent on an annular member of a heterocycle or an annular member of a heterocycle, either carbon or a heteroatom, or a substituent at the C- or N-terminus of the oligomer, depending upon convenience.
  • a radiolabel as part of the oligomer, one avoids any significant change in the spatial conformation of the oligomer.
  • the radiolabel may serve numerous purposes in diagnostics, cytohistology, radiotherapy, and the like.
  • either terminus of the oligomer may be used for special purposes depending upon the use to which the oligomer is put.
  • the oligomer may be linked to labels, such as fluorescers, e.g. dansyl, fluorescein, Texas red, isosulfan blue, ethyl red, malachite green, etc., chemiluminescers, particles, e.g. magnetic particles, colloidal particles, e.g. gold particles, light sensitive bond forming compounds, e.g.
  • chelating compounds such as EDTA, NTA, tartaric acid, ascorbic acid, polyhistidines of from 2 to 8 histidines, alkylene polyamines, etc., chelating antibiotics, such as bleomycin, where the chelating compounds may chelate a metal atom, such as iron, cobalt, nickel, technetium, etc.
  • intercalating dyes such as ethidium bromide, thiazole orange, thiazole blue, TOTO, 4' , 6- diamidino-2-phenylindole (DAPI), etc.
  • enzymes such as ⁇ -galactosidase, NADH or NADHP dehydrogenase, malate dehydrogenase, lysozyme, peroxidase, luciferase, etc.
  • alkylating agents such as haloacetamides, N-ethyl nitrosourea, nitrogen and sulfur mustards, sulfonate esters, etc.
  • alkylating agents such as haloacetamides, N-ethyl nitrosourea, nitrogen and sulfur mustards, sulfonate esters, etc.
  • other compounds such as arylboronic acids, tocopherols, lipoic acid, captothesin, etc. colloidal particles, e.g. gold particles, fluorescent particles, peroxides, DNA cleaving agents, oligonucleotides, oligopeptides, nmr agents, stable free radicals, metal atoms, etc.
  • the oligomer may be combined with other labels, such as haptens for which a convenient receptor exists, e.g.
  • the oligomers may be joined to sulfonated or phosphonated aromatic groups, e.g. naphthalene, to enhance inhibition of transcription, particularly of viruses (Clanton et al., Antiviral Res. (1995) 27:335 -354). In some instances, one may bond multiple copies of the subject oligomers to polymers, where the subject oligomers are pendant from the polymer.
  • Polymers particularly water soluble polymers, which may find use are cellulose, poly (vinyl alcohol), poly(vinyl acetate-vinyl alcohol), polyacrylates, and the like.
  • the number of oligomers may be from 1 to about 1 :5 monomer units of the polymer.
  • the nucleotides will normally be associated with the proximal or bordering nucleic acid sequence of the target sequence, whereby the attached nucleic acid sequence will complex with the nucleotides in the major groove.
  • the different molecules may be joined to the termini in a variety of ways, depending upon the available functionality (ies) present at the termini, such as extending the polar substituted alkyl group, e.g. having a chain of more than 6 carbon atoms, providing for a substituent at a terminus which can be reacted with the moiety to be added, where such substituents will conventionally be amino, hydroxyl, mercapto, carboxyl, phosphate, etc., so as to form amides, both organic and inorganic, substituted amines (reductive amination), ethers, thioethers, disulfides, esters, both organic and inorganic, pyrophosphates, and the like.
  • the molecules may be introduced as part of the synthetic scheme, displacing the oligomer from the solid support on which the oligomer is synthesized. Because the compounds of the subject invention may be used in such a variety of ways, no simple description is appropriate to the variety of moieties to which the subject oligomers may be bound, nor the specific molecular weights of the resulting products.
  • the subject oligomers may be synthesized on supports, e.g. chips, where by using automated synthetic techniques, different oligomers may be synthesized at individual sites. In this way, an array of different oligomers may be synthesized, which can then be used to identify the presence of a plurality of different sequences in a sample.
  • an array of different oligomers may be synthesized, which can then be used to identify the presence of a plurality of different sequences in a sample.
  • By knowing the composition of the oligomer at each site one can identify binding of specific sequences at that site by various techniques, such as labeled antiDNA antibodies, linkers having complementary restriction overhangs, where the sample DNA has been digested with a restriction enzyme, and the like.
  • the techniques for preparing the subject arrays are analogous to the techniques used for preparing oligopeptide arrays, as described in Cho et al. , Science, 1993, 261 , 1303-1305.
  • the complex will usually comprise one or two oligomers or combinations of one or two oligomers, where individual or pairs of oligomers specifically interact with a dsDNA sequence of at least 6, usually at least 7 and preferably 8 or more bp, frequently not more than 40 bp, more usually not more than about 30 bp, preferably not more than 20 bp.
  • the core oligomer may be further substituted for specific applications as described above.
  • a core molecule or core molecules which define at least complementary pairs of heterocycles, and include at least one of an aliphatic amino acid and a polar group substituted alkyl.
  • This core molecule which is the centerpiece of the invention can serve as the nexus for numerous substitutions which do not interfere with the basic function of the core molecule, although where the binding affinity is greater than is necessary for the function, some degradation of the binding affinity is permitted. Therefore, in defining the compounds of this invention, it should be understood that many variations are permitted, where the basic core or unit structure is retained, while the core or unit structure is modified with one or more substituents to impart desired properties to the molecule for its intended function.
  • the subject compounds are compounds which have at least one organic cyclic group, particularly N-methyl imidazole, which has specificity for one nucleotide, which is present as a complementary pair.
  • the subject compounds will have at least one of these complementary pairs, frequently at least two of these complementary pairs, and generally fewer than 75% of the complementary pairs will have the organic cyclic group having specificity for a single nucleotide.
  • the N-methyl imidazole there will usually be at least one Im/Py pair, desirably not having more than three, frequently having not more than two, of such pairs consecutively, so that there will frequently be not more than three Im's in a row.
  • the Im/Py pair provide for greater specificity, but contribute less than the Py/Py pair to the binding affinity for the dsDNA. Therefore, by appropriate selection of the target sequence, one may optimize for binding affinity and specificity.
  • ⁇ -alanine associates with T-A pairs and will usually form a complementary pair with itself.
  • ⁇ -alanine may be used in juxtaposition to T or A and as a complementary pair with itself with a T-A pair.
  • the binding affinity K ⁇ as determined in the Experimental section will be greater than 5 x 10 8 M “1 , usually greater than 10 9 M "1 , preferably greater than about 10 10 M "1 , so as to be able to bind to the target sequence at subnanomolar concentrations in the environment in which they are used.
  • the difference in affinity with a single mismatch will be at least 3 fold, usually at least 5 fold, preferably at least 10 fold and frequently greater than 20 fold, and may be 100 fold or more.
  • the oligomers of the subject invention will generally have a molecular weight of less than about 5kD, preferably less than about 3.5kD, and will generally have a molecular weight of at least about .6kD, more usually at least about .8kD.
  • compositions of the subject invention for complexing with dsDNA will have from one to two oligomers, or combinations thereof, depending upon whether there is a hairpin turn in the oligomer, where only one oligomer is necessary, or there is no hairpin turn, so that for complementarity, one needs two oligomers. More oligomers may be used, where one wishes to target more than one dsDNA sequence, for example, contiguous or proximal sequences, to enhance the overall specificity, or for distal sequences, where the sequences may be associated with the same functional unit, e.g. a gene, or different functional units, e.g. homeodomains.
  • the composition, whether a single oligomer or a combination of oligomers will provide at least three complementary pairs in the single oligomer or pair of oligomers.
  • N-methyl pyrrole and N-methyl imidazole are exemplary of the class of compounds of the subject invention. These compounds may be prepared in accordance with the procedures described herein. When used, Py will refer to N-methyl pyrrole and Im will refer to N-methyl imidazole.
  • Imlm- ⁇ -Im- ⁇ -Py- ⁇ -PyPyPyPy- ⁇ -Py Imlm- ⁇ -Im- ⁇ -Py- ⁇ -Py, Im- ⁇ -ImPyPy- ⁇ -ImlmPy- ⁇ -Py, ImlmPy- ⁇ - Py- ⁇ -Im- ⁇ -ImPyPy, Imlm- ⁇ -Im- ⁇ -PylmPyPy.
  • Figure 1 illustrates the relationship between the azoles and the nucleotides of the minor groove.
  • the oligomers may be completely overlapped, or only partially overlapped, i.e. slipped or have overhangs.
  • the overlapped configuration all of the azoles are in complementary pairs, as well as any spacing amino acid.
  • the slipped configuration there will be at least one azole ring which is unpaired in at least one of the oligomers, usually there will be at least two azole rings, more usually, in both of the oligomers.
  • unpaired azole rings will be in the range of 2 to 30, more usually 2 to 20, frequently 2 to 12.
  • unpaired azoles will involve chains of 2 or more azole rings, more usually 3 or more azole rings, including, as appropriate, aliphatic amino acids in the chain.
  • oligomers may be used.
  • these otherwise unpaired members of one oligomer can be positioned to form complementary pairs with the extension or overhang of the unpaired members of the other oligomer.
  • the subject compositions may be brought together with the dsDNA under a variety of conditions.
  • the conditions may be in vitro, in cell cultures, ex vivo or in vivo.
  • the dsDNA may be extracellular or intracellular. When extracellular, the dsDNA may be in solution, in a gel, on a slide, or the like.
  • the dsDNA may be present as part of a whole chromosome or fragment thereof of one or more centiMorgans.
  • the dsDNA may be part of an episomal element.
  • the dsDNA may be present as smaller fragments ranging from about 20, usually at least about 50, to a million base pairs, or more.
  • the dsDNA may be intracellular, chromosomal, mitochondrial, plastid, kinetoplastid, or the like, part of a lysate, a chromosomal spread, fractionated in gel elecrophoresis, a plasmid, or the like, being an intact or fragmented moiety.
  • the formation of complexes between dsDNA and the subject compounds may be for diagnostic, therapeutic, purification, or research purposes, and the like. Because of the specificity of the subject compounds, the subject compounds can be used to detect specific dsDNA sequences in a sample without melting of the dsDNA.
  • the diagnostic purpose for the complex formation may be detection of alleles, identification of mutations, identification of a particular host, e.g.
  • the pathogens may be viruses, bacteria, fungi, protista, chlamydia, or the like.
  • the hosts may be vertebrates or invertebrates, including insects, fish, birds, mammals, and the like or members of the plant kingdom.
  • the dsDNA When involved in vitro or ex vivo, the dsDNA may be combined with the subject compositions in appropriately buffered medium, generally at a concentration in the range of about 0.1 nM to 1 mM.
  • buffers may be employed, such as TRIS, HEPES, phosphate, carbonate, or the like, the particular buffer not being critical to this invention.
  • conventional concentrations of buffer will be employed, usually in the range of about 10-200mM.
  • Other additives which may be present in conventional amounts include sodium chloride, generally from about 1-250 mM, dithiothreitol, and the like.
  • the pH will generally be in the range of about 6.5 to 9.
  • the target dsDNA may be present in from about 0.001 to 100 times the moles of oligomer.
  • the subject compounds when used in diagnosis may have a variety of labels as indicated previously and may use many of the protocols that have been used for detection of haptens and receptors (immunoassays) or with hybridization (DNA complementation). Since the subject compounds are not nucleic acids, they can be employed more flexibly than when using DNA complementation.
  • the assays are carried out as described below and then depending on the nature of the label and protocol, the determination of the presence and amount of the sequence may then be made.
  • the protocols may be performed in solution or in association with a solid phase.
  • the solid phase may be a vessel wall, a particle, fiber, film, sheet, or the like, where the solid phase may be comprised of a wide variety of materials, including gels, paper, glass, plastic, metals, ceramics, etc.
  • Either the sample or the subject compounds may be affixed to the solid phase in accordance with known techniques.
  • the subject compounds may be covalently bound to the solid phase.
  • the sample may be covalently or non-covalently bound to the solid phase, in accordance with the nature of the solid phase.
  • the solid phase allows for a separation step, which allows for detection of the signal from the label in the absence of unbound label.
  • Exemplary protocols include combining a cellular lysate, with the DNA bound to the surface of a solid phase, with an enzyme labeled oligomer, incubating for sufficient time under complex forming conditions for the oligomer to bind to any target sequence present on the solid phase, separating the liquid medium and washing, and then detecting the presence of the enzyme on the solid phase by use of a detectable substrate.
  • a number of protocols are based on having a label which does not give a detectable signal directly, but relies on non-covalent binding with a receptor, which is bound to a surface or labeled with a directly detectable label.
  • a hapten e.g. digoxin
  • the sample DNA would be bound to a surface, so as to remain bound to the surface during the assay process.
  • the oligomer would be added and bind to any target sequence present. After washing to remove oligomer, enzyme or fluorescer labeled antidigoxin monclonal antibody is added, the surface washed and the label detected.
  • the oligomers are combined with the DNA in the liquid phase and incubated. After completion of the incubation, the sample is combined with the receptor for the biotin or hapten, e.g. avidin or antibody, bound to a solid surface. After a second incubation, the surface is washed and the level of fluorescence determined.
  • two labels which interact for example, two enzymes, where the product of one enzyme is the substrate of the other enzyme, or two fluorescers, where there can be energy transfer between the two fluorescers, one can determine when complex formation occurs, since the two labels will be brought into juxtaposition by forming the 2: 1 complex in the minor groove.
  • the two enzymes one detects the product of the second enzyme and with the two fluorescers, one can determine fluorescence at the wavelength of the Stokes shift or reduction in fluorescence of the fluorescer absorbing light at the lower wavelength.
  • Another protocol would provide for binding the subject compositions to a solid phase and combining the bound oligomers with DNA in solution. After the necessary incubations and washings, one could add labeled antiDNA to the solid phase and determine the amount of label bound to the solid phase.
  • an antiDNA antibody indicating the presence of the target sequence.
  • protocols that may be used is legion. Illustrative protocols may be found for DNA assays in WO95/20591; EPA 393,743; WO86/05519; and EPA 278,220, while protocols and labels which may be adapted from immunoassays for use with the subject compositions for assays for DNA may be found in WO96/20218; WO95/06115; WO94/04538; WO94/01776; WO92/14490; EPA 537830; WO91/09141 ; WO91/06857; and WO91/05257.
  • the non- specifically bound oligomers may be removed. This can be achieved by combining the cells with a substantial excess of the target sequence, conveniently attached to particles. By allowing for the non-specifically bound oligomers to move to the extracellular medium, the oligomers will become bound to the particles, which may then be readily removed. If desired, one may take samples of cells over time and plot the rate of change of loss of the label with time. Once the amount of label becomes stabilized, one can relate this value to the presence of the target sequence. Other techniques may also be used to reduce false positive results.
  • compositions may also be used to titrate repeats, where there is a substantial change, increase or decrease, in the number of repeats associated with a particular indication.
  • the number of repeats should be at least an increase of 50% , preferably at least two-fold, more preferably at least three-fold.
  • the subject compositions may be used for isolation and/or purification of target DNA comprising the target sequence.
  • the subject oligomers where the oligomers are bound to a solid phase, those portions of a DNA sample which have the target sequence will be bound to the subject oligomers and be separated from the remaining DNA.
  • a target DNA sequence of interest for example, a gene comprising an expressed sequence tag (EST), a transcription regulatory sequence to which a transcription factor binds, a gene for which a fragment is known, and the like.
  • EST expressed sequence tag
  • the subject oligomers allow for isolation of restriction fragments, which can be separated on a gel and then sequenced. In this way the gene may be rapidly isolated and its sequence determined. As will be discussed below, the subject oligomers may then be used to define the function of the gene.
  • the subject oligomers may be used in a variety of ways in research. Since the subject oligomers can be used to inhibit transcription, the effect of inhibiting transcription on cells, cell assemblies and whole organisms may be investigated.
  • the subject compositions may be used in conjunction with egg cells, fertilized egg cells or blastocysts, to inhibit transcription and expression of particular genes associated with development of the fetus, so that one can identify the effect of reduction in expression of the particular gene.
  • the gene may be involved in regulation of a number of other genes, one can define the effect of the absence of such gene on various aspects of the development of the fetus.
  • the subject oligomers can be designed to bind to homeodomains, so that the transcription of one or more genes may be inhibited.
  • By inhibiting transcription one can provide for a reversible "knock out," where by providing for continuous intravenous administration, one can greatly extend the period in which the transcription of the gene is inhibited.
  • genes by downregulating other genes.
  • one expression product inhibits the expression of another expression product, by inhibiting the expression of the first product, one can enhance the expression of the second product.
  • transcription factors involve a variety of cofactors to form a complex, one can enhance complex formation with one transcription factor, as against another transcription factor, by inhibiting expression of the other transcription factor. In this way one can change the nature of the proteins being expressed, by changing the regulatory environment in the cell.
  • the target sequence may be associated with the 5 '-untranslated region, namely the transcriptional initiation region, an enhancer, which may be in the 5 '-untranslated region, the coding sequence or introns, the coding region, including introns and exons, the 3'- untranslated region, or distal from the gene.
  • an enhancer which may be in the 5 '-untranslated region, the coding sequence or introns, the coding region, including introns and exons, the 3'- untranslated region, or distal from the gene.
  • the subject compositions may be presented as liposomes, being present of the lumen of the liposome, where the liposome may be combined with antibodies to surface membrane proteins or basement membrane proteins, ligands for cellular receptors, or other site directing compound, to localize the subject compositions to a particular target.
  • liposomes may be presented as liposomes, being present of the lumen of the liposome, where the liposome may be combined with antibodies to surface membrane proteins or basement membrane proteins, ligands for cellular receptors, or other site directing compound, to localize the subject compositions to a particular target.
  • the subject compositions may be administered by catheter to localize the subject compositions to a particular organ or target site in the host.
  • concentration at the site of interest should be at least about 0. InM, e.g. intracellular or in the extracellular medium, preferably at least about InM, usually not exceeding ImM, more usually not exceeding about lOOnM.
  • concentration of the oligomers extracellularly will generally be greater than the desired intracellular concentration, ranging from about 2 to 1000 times or greater the desired intracellular concentration.
  • the higher concentrations may be employed, and similarly, where the affinities are high enough, and the effect can be achieved with lower concentrations, the lower concentrations may also be employed.
  • the subject compositions can be used to modulate physiological processes in vivo for a variety of reasons.
  • non-primates particularly domestic animals, in animal husbandry and breeding, one can affect the development of the animal by controlling the expression of particular genes, modify physiological processes, such as accumulation of fat, growth, response to stimuli, etc.
  • Domestic animals include feline, murine, canine, lagomorpha, bovine, ovine, canine, porcine, etc.
  • compositions may used therapeutically to inhibit proliferation of particular target cells, inhibit the expression of one or more genes related to an indication, change the phenotype of cells, either endogenous or exogenous to the host, where the native phenotype is detrimental to the host.
  • change the phenotype of cells either endogenous or exogenous to the host, where the native phenotype is detrimental to the host.
  • Various techniques may be used to enhance transport across the bacterial wall, such as various carriers or sequences, such as polylysine, poly(E-K), nuclear localization signal, cholesterol and cholesterol derivatives, liposomes, protamine, lipid anchored polyethylene glycol, phosphatides, such as dioleoxyphosphatidylethanolamine, phosphatidyl choline, phosphatidylglycerol, ⁇ -tocopherol, cyclosporin, etc.
  • the subject compositions may be mixed with the carrier to form a dispersed composition and used as the dispersed composition.
  • the subject compositions can be used to inhibit the proliferation by inhibiting transcription of essential genes.
  • cancers such as sarcomas, carcinomas and leukemias, restenosis, psoriasis, lymphopoiesis, atherosclerosis, pulmonary fibrosis, primary pulmonary hypertension, neurofibromatosis, acoustic neuroma, tuberous sclerosis, keloid, fibrocystic breast, polycystic ovary and kidney, scleroderma, rheumatoid arthritis, ankylosing spondilitis, myelodysplasia, cirrhosis, esophageal stricture, sclerosing cholangitis, retroperitoneal fibrosis, etc.
  • Inhibition may be associated with one or more specific growth factors, such as the families of platelet- derived growth factors, epidermal growth factors, transforming growth factor, nerve growth factor, fibroblast growth factors, e.g. basic and acidic, keratinocyte fibroblast growth factor, tumor necrosis factors, interleukins, particularly interleukin 1, interferons, etc.
  • specific growth factors such as the families of platelet- derived growth factors, epidermal growth factors, transforming growth factor, nerve growth factor, fibroblast growth factors, e.g. basic and acidic, keratinocyte fibroblast growth factor, tumor necrosis factors, interleukins, particularly interleukin 1, interferons, etc.
  • a specific gene which is associated with a disease state such as mutant receptors associated with cancer, inhibition of the arachidonic cascade, inhibition of expression of various oncogenes, including transcription factors, such as ras, myb, myc, sis, src, yes, fps/fes, erbA, erbB, ski, jun, crk, sea, rel, fms, abl, met, trk, mos, Rb-1, etc.
  • T-cell receptors are associated with autoimmune diseases, such as multiple sclerosis, diabetes, lupus erythematosus, myasthenia gravis, Hashimoto's disease, cytopenia, rheumatoid arthritis, etc.
  • the expression of the undesired T-cell receptors may be diminished, so as to inhibit the activity of the T-cells.
  • TNF enzymes which produce singlet oxygen, such as peroxidases and superoxide dismutase, proteases, such as elastase, INF ⁇ , IL-2, factors which induce proliferation of mast cells, eosinophils, IgG ⁇ IgE, regulatory T cells, etc.
  • compositions include modulating levels of receptors, production of ligands, production of enzymes, production of factors, reducing specific cell populations, changing phenotype and genotype of cells, particularly as associated with particular organs and tissues, modifying the response of cells to drugs or other stimuli, e.g. enhancing or diminishing the response, inhibiting one of two or more alleles, repressing expression of target genes, particularly as related to clinical studies, modification of behavior, modification of susceptibility to disease, response to stimuli, response to pathogens, response to drugs, therapeutic or substances of abuse, etc.
  • compositions may be employed or combinations, directed to the same dsDNA region, but different target sequences, contiguous or distal, or different DNA regions.
  • the composition may have one or a plurality of oligomers or pairs of oligomers which will be directed to different target sites.
  • the subject compositions may be used as a sole therapeutic agent or in combination with other therapeutic agents. Depending upon the particular indication, other drugs may also be used, such as antibiotics, antisera, monoclonal antibodies, cytokines, anti-inflammatory drugs, and the like.
  • the subject compositions may be used for acute situations or in chronic situations, where a particular regimen is devised for the treatment of the patient.
  • the compositions may be prepared in physiologically acceptable media and stored under conditions appropriate for their stability. They may be prepared as powders, solutions or dispersions, in aqueous media, alkanols, e.g. ethanol and propylene glycol, in conjunction with various excipients, etc.
  • the particular formulation will depend upon the manner of administration, the desired concentration, ease of administration, storage stability, and the like.
  • the concentration in the formulation will depend upon the number of doses to be administered, the activity of the oligomers, the concentration required as a therapeutic dosage, and the like.
  • the subject compositions may be administered orally, parenterally, e.g. intravenously, subcutaneously, intraperitoneally, transdermally, etc.
  • the subject compositions may be formulated in accordance with conventional ways, associated with the mode of treatment. As a result of the formulation, the subject compositions are introduced into the cells, either as a directed introduction to a specific cell target or as random introduction into a number of different cell types.
  • the subject compositions will only have an effect in those cells in which the target dsDNA is being transcribed or there is some other mechanism whereby the binding of the subject compositions can affect the mechanism. In this way selectivity can be achieved, since the only productive result will be in cells where the target dsDNA has an effect which is modified by the binding of the subject compositions to the dsDNA.
  • the subject compounds may be prepared, conveniently employing a solid support.
  • the oligomer is grown on the solid phase attached to the solid phase by a linkage which can be cleaved by a single step process.
  • the addition of an aliphatic amino acid at the C-terminus of the oligomers allows the use of Boc- ⁇ -alanine-Pam-resin which is commercially available in appropriate substitution levels (0.2mmol/g). Aminolysis may be used for cleaving the polyamide from the support.
  • Example 1 Solid phase synthesis of polyamides containing imidazole and pyrrole amino acids 1
  • Boc- ⁇ -alanine-(4-carboxamidomethyl)-benzyl-ester- copoly(styrene-divinylbenzene) resin Boc- ⁇ -alanine-Pam-Resin
  • dicyclohexylcarbodiimide DCC
  • hydroxybenzotriazole HOBt
  • 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate Boc-glycine
  • Boc- ⁇ -alanine were purchased from Peptides International.
  • N,N-diisopropylethylamine DIEA
  • N,N-dimethylformamide DMF
  • N-methylpyrrolidone NMP
  • DMSO/NMP DMSO/NMP
  • Boc- ⁇ -aminobutyric acid was from NOVA Biochem, dichloromethane (DCM) and triethylamine (TEA) was reagent grade from EM, thiophenol (PhSH), dimethylaminopropylamine, trichloroacetyl chloride, N-methylpyrrole, and N-methylimidazole from Aldrich, and trifluoroacetic acid (TFA) from Halocarbon. All reagents were used without further purification.
  • N-methylpyrrole (0.45 kg, 5.5 mole) in 1.5 liter anhydrous ethyl ether.
  • the reaction was stirred for an additional 3 hours and quenched by the dropwise addition of a solution of 400 g potassium carbonate in 1.5 liters water.
  • the layers were separated and the ether layer concentrated in vacuo to provide 2-(trichloroacetyl)pyrrole (1.2 kg, 5.1 mol) as a yellow crystalline solid sufficiently pure to be used without further purification.
  • Methyl-4-nitropyrrole-2-carboxylate 4 (450 g, 2.8 mol) was dissolved in ethyl acetate (8 L). A slurry of 40 g of 10% Pd/C in 800 mL ethyl acetate was then added and the mixture stirred under a slight positive pressure of hydrogen (c.a. 1.1 atm) for 48 h. Pd/C was removed by filtration through celite, washed 1 x 50 mL ethyl acetate, and the volume of the mixture reduced to c.a. 500 mL. 7 L of cold ethyl ether was added and HCl gas gently bubbled through the mixture. The precipitated amine hydrochloride was then collected by vacuum filtration to yield a white powder (380 g, 81.6 %).
  • Methyl 4-amino-l-methyl-pyrrole-2-carboxylate hydrochloride (340 g, 1.8 mol) was dissolved in 1 L of 10% aqueous sodium carbonate in a 3 L flask equipped with a mechanical stirrer, di-t-butyldicarbonate (400 g, 2.0 mmol) slurried in 500 mL of dioxane was added over a period of thirty min. , maintaining a temperature of 20°C The reaction was allowed to proceed for three h and was determined complete by TLC, cooled to 5°C for 2 h and the resulting white precipitate collected by vacuum filtration.
  • the Boc -pyrrole ester contaminated with Boc-anhydride was dissolved in 700 mL MeOH, 700 mL of 2M NaOH was added and the solution heated at 60°C for 6 h.
  • the reaction was cooled to room temperature, washed with ethyl ether (4 x 1000 mL), the pH of the aqueous layer reduced to c.a. 3 with 10% (v/v) H 2 S0 4 , and extracted with ethyl acetate (4 x 2000 mL).
  • the combined ethyl acetate extracts were dried (sodium sulfate) and concentrated in vacuo to provide a tan foam.
  • the foam was dissolved in 500 mL of DCM and 2 L petroleum ether added, the resulting slurry was concentrated in vacuo.
  • the reaction was redissolved and concentrated three additional times to provide a fine white powder (320 g, 78 % yield).
  • Ethyl 1 -methylimidazole-2-carboxylate N-methylimidazole (320 g, 3.9 mol) was combined with 2 L acetonitrile and 1 L triethylamine in a 12 L flask equipped with a mechanical stirrer and the solution cooled to -20°C Ethyl chloroformate (1000 g, 9.2 mol) was added with stirring, keeping the temperature between -20°C and -25 °C The reaction was allowed to slowly warm to room temperature and stir for 36 h.
  • Ethyl 1 -methy l-4-nitroimidazole-2-carboxylate was carefully dissolved in 1000 mL of concentrated sulfuric acid cooled to 0°C 90% nitric acid (1 L) was slowly added maintaining a temperature of 0°C The reaction was then refluxed with an efficient condenser (-20°C) in a well ventilated hood for 50 min. The reaction was cooled with an ice bath, and quenched by pouring onto 10 L ice.
  • Ethyl l-methyl-4-nitroimidazole-2-carboxylate (103 g, 520 mmol) was dissolved in 5 L of 1: 1 ethanol/ethyl acetate. 20 g 10% Pd/C slurried in 500 mL ethyl acetate was added and the mixture stirred under a slight positive pressure of hydrogen (c.a. 1.1 atm) for 48 h. The reaction mixture was filtered, concentrated in vacuo to a volume of 500 mL and 5 L of cold anhydrous ethyl ether added. Addition of HCl gas provided a white precipitate. The solution was cooled at -20°C for 4 h and the precipitate collected by vacuum filtration and dried in vacuo to provide (75 g, 78% yield) of a fine white powder.
  • Ethyl 4-amino-l-methylimidazole-2-carboxylate hydrochloride 75 g, 395 mmol was dissolved in 200 mL DMF.
  • DIE A 45 mL, 491 mmol was added followed by di-t-butyldicarbonate (99 g, 491 mmol).
  • the mixture was shaken at 60°C for 18 h, allowed to assume room temperature, and partitioned between 500 mL brine, 500 mL ethyl ether.
  • the ether layer was extracted with (2 x 200 mL each) 10% citric acid, brine, satd.
  • Boc-ester contaminated with 20% Boc-anhydride as indicated by ⁇ NMR.
  • the Boc-ester used without further purification, was dissolved in 200 mL 1 M NaOH. The reaction mixture was allowed to stand for 3 h at 60°C with occasional agitation. The reaction mixture was cooled to 0°C, and carefully neutralized with 1 M HCl to pH 2, at which time a white gel formed. The gel was collected by vacuum filtration, frozen before drying, and remaining water lyophilized to yield a white powder.
  • Imidazole-2-carboxylic acid ( ⁇ -aminobutyric acid, Boc-glycine, and Boc- ⁇ -alanine.
  • the appropriate amino acid or acid (2 mmol) was dissolved in 2 mL DMF.
  • HBTU 720 mg, 1.9 mmol was added followed by DIEA (1 mL) and the solution lightly shaken for at least 5 min.
  • Boc-imidazole acid (257 mg, 1 mmol) and HOBt (135 mg, 1 mmol) were dissolved in 2 mL DMF, DCC (202 mg, 1 mmol) is then added and the solution allowed to stand for at least 5 min.
  • DCC 202 mg, 1 mmol
  • Boc-Pyrrole acid (514 mg, 2 mmol) was dissolved in 2 mL dichloromethane, DCC
  • Boc- ⁇ -alanine-Pam-Resin (1.25 g, 0.25 mmol) is placed in a 20 mL glass reaction vessel, shaken in DMF for 5 min and the reaction vessel drained.
  • the resin was washed with DCM (2 x 30 s.) and the Boc group removed with 80% TFA/DCM/0.5 M PhSH, 1 x 30 s., 1 x 20 min.
  • the resin was washed with DCM (2 x 30 s.) followed by DMF (1 x 30 s.).
  • a resin sample (5 - 10 mg) was taken for analysis.
  • the vessel was drained completely and activated monomer added, followed by DIEA if necessary.
  • the reaction vessel was shaken vigorously to make a slurry. The coupling was allowed to proceed for 45 min, and a resin sample taken.
  • the reaction vessel was then washed with DCM, followed by DMF.
  • Machine- assisted synthesis was performed on a ABI 430A synthesizer on a 0.18 mmol scale (900 mg resin; 0.2 mmol/gram).
  • Each cycle of amino acid addition involved deprotection with approximately 80% TFA/DCM/0.4 M PhSH for 3 minutes, draining the reaction vessel, and then deprotection for 17 minutes; 2 dichloromethane flow washes; an NMP flow wash; draining the reaction vessel; coupling for 1 hour with in situ neutralization, addition of dimethyl sulfoxide (DMSO)/NMP, coupling for 30 minutes, addition of DIEA, coupling for 30 minutes; draining the reaction vessel; washing with DCM, taking a resin sample for evaluation of the progress of the synthesis by HPLC analysis; capping with acetic anhydride/DIEA in DCM for 6 minutes; and washing with DCM.
  • a double couple cycle is employed when coupling aliphatic amino acids to imidazole, all other couplings are performed with single couple cycles.
  • the ABI 430A synthesizer was left in the standard hardware configuration for
  • Reagent positions 1 and 7 were DIEA, reagent position 2 was TFA/0.5 M thiophenol, reagent position 3 was 70% ethanolamine/ methanol, reagent position 4 was acetic anhydride, reagent position 5 was DMSO/NMP, reagent position 6 was methanol, and reagent position 8 was DMF.
  • New activator functions were written, one for direct transfer of the cartridge contents to the concentrator (switch list 21, 25, 26, 35, 37, 44), and a second for transfer of reagent position 8 directly to the cartridge (switch list 37, 39, 45, 46).
  • Boc-Py-OBt ester (357 mg, 1 mmol) was dissolved in 2 mL DMF and filtered into a synthesis cartridge. Boc-Im acid monomer was activated (DCC/HOBt), filtered, and placed in a synthesis cartridge. Imidazole-2-carboxylic acid was added manually. At the initiation of the coupling cycle the synthesis was interrupted, the reaction vessel vented and the activated monomer added directly to the reaction vessel through the resin sampling loop via syringe. When manual addition was necessary an empty synthesis cartridge was used. Aliphatic amino acids (2 mmol) and HBTU (1.9 mmol) were placed in a synthesis cartridge. 3 mL of DMF was added using a calibrated delivery loop from reagent bottle 8, followed by calibrated delivery of 1 mL DIEA from reagent bottle 7, and a 3 minute mixing of the cartridge.
  • the activator cycle was written to transfer activated monomer directly from the cartridge to the concentrator vessel, bypassing the activator vessel. After transfer, 1 mL of DIEA was measured into the cartridge using a calibrated delivery loop, and the DIEA solution combined with the activated monomer solution in the concentrator vessel. The activated ester in 2: 1 DMF/DIEA was then transferred to the reaction vessel. All lines were emptied with argon before and after solution transfers.
  • ImPyPy-(-PyPyPy- ⁇ -alanine-Pam-Resin was prepared by machine-assisted synthesis protocols.
  • a sample of resin (1 g, 0.17 mmol) was placed in a 20 mL glass scintillation vial, 4 mL of dimethylaminopropylamine added, and the solution heated at 55°C for 18 h. Resin is removed by filtration through a disposable propylene filter and 16 mL of water added.
  • the polyamide/amine mixture was purified directly by preparatory HPLC and the appropriate fractions lyophilized to yield a white powder.
  • a resin sample (c.a. 4 mg) was placed in a 4 mL glass test tube, 200 :L of N,N-dimethylaminopropylamine was added and the mixture heated at 100°C for 5 min. The cleavage mixture was filtered and a 25 :L sample analyzed by analytical HPLC at 254 nm.
  • Example 2 ⁇ -alanine and ⁇ -aminobutyric acid are turn and overlapped specific "guide” amino acids which may be combined predictably within the same molecule.
  • Polyamides were prepared in high purity using solid phase synthetic methodology as described above. Polyamides were assembled in a stepwise manner on Boc- ⁇ -alanine-Pam resin and Boc-glycine-Pam-resin respectively. Polyamides ImPyPy- ⁇ - aminobutyric acid-ImPyPy- ⁇ -alanine-Dp, ImPyPy- ⁇ -aminobutyric acid-ImPyPy- ⁇ -alanine- PyPyPy-G-Dp and ImPyPy- ⁇ -aminobutyric acid-ImPyPy- ⁇ -alanine-PyPyPy-G-Dp-NH 2 were cleaved from the support with an appropriate primary amine and purified by reversed-phase HPLC to provide 10-30 mg of polyamide.
  • a primary amine group suitable for post-synthetic modification can be provided.
  • Amine modified polyamides are treated with an excess of the dianhydride of EDTA, unreacted anhydride hydrolyzed, and the EDTA modified polyamide ImPyPy- ⁇ -aminobutyric acid-ImPyPy- ⁇ - alanine-PyPyPy-G-Dp-EDTA isolated by reversed-phase HPLC. Polyamides were cleaved from the support.
  • Polyamide was prepared by machine-assisted solid phase methods as a white powder (29 mg, 59% recovery).
  • ImPyPy- ⁇ -aminohutyric cid-ImPvPy- ⁇ -alanine-PyPyPy-G-Dp-EDTA EDTA-dianhydride 50 mg was dissolved in 1 mL DMSO/NMP solution and 1 mL DIEA by heating at 55 °C for 5 min. The dianhydride solution was added to ImPyPy- ⁇ -aminobutyric acid-ImPyPy- ⁇ -alanine-PyPyPy-G-Dp-NH 2 (9.0 mg, 5 ⁇ mol) dissolved in 750 ⁇ L DMSO.
  • the mixture was heated at 55°C for 25 min, treated with 3 mL 0.1 M NaOH, and heated at 55 °C for 10 min.
  • 0.1 % TFA was added to adjust the total volume to 8 mL and the solution purified directly by reversed-phase HPLC to provide ImPyPy- ⁇ -aminobutyric acid-ImPyPy- ⁇ -alanine-PyPyPy-G-Dp-EDTA as a white powder (3 mg, 30% recovery after HPLC purification).
  • Plasmid pJT8 was prepared by hybridizing two sets of 5'-phosphorylated complementary oligonucleotides, 5'-CCGGGAACGTAGCGTACCGGTCGCAAAAAGACAGGCTCGA-3' , and 5 ' -GGCGTCGAGCCTGTCTTTTTGCGACCGGTACGCTACGTTC-3 ' , and
  • the 3'- 32 P end-labeled Aflll/Fspl fragment was prepared by digesting the plasmid with AflH and simultaneously filling in using Sequenase, ["- 32 P]-deoxyadenosine-5'-triphosphate, and ["- 32 P]-thymidine-5'-triphosphate, digesting with Fspl, and isolating the 247 bp fragment by nondenaturing gel electrophoresis.
  • the 5'- 32 P-end-labeled Aflll/Fspl fragment was prepared using standard methods. A and G sequencing were carried out as described. 3 Standard methods were used for all DNA manipulations. 4
  • Reactions were precipitated and the cleavage products separated using standard methods. Next, 10 ⁇ L of a solution containing calf thymus DNA (140 mM base-pair) (Pharmacia) and glycogen (2.8 mg/mL) was added, and the DNA precipitated. The reactions were resuspended in lx TBE/80% formamide loading buffer, denatured by heating at 85°C for 10 min, and placed on ice. The reaction products were separated by electrophoresis on an 8% polyacrylamide gel (5% crosslink, 7 M urea) in lx TBE at 2000 V. Gels were dried and exposed to a storage phosphor screen. Relative cleavage intensities were determined by volume integration of individual cleavage bands using ImageQuant software.
  • Footprinting reactions were initiated by the addition of 10 mL of a DNase I stock solution (at the appropriate concentration to give ⁇ 55% intact DNA) containing 1 mM dithiothreitol and allowed to proceed for seven min at 22°C The reactions were stopped by the addition of 50 ⁇ L of a solution containing 2.25 M NaCl, 150 mM EDTA, 0.6 mg/mL glycogen, and 30 mM base-pair calf thymus DNA, and ethanol precipitated. Reactions were resuspended in lx TBE/80% formamide loading buffer, denatured by heating at 85 °C for 10 min, and placed on ice.
  • reaction products were separated by electrophoresis on an 8% polyacrylamide gel (5% crosslink, 7 M urea) in lx TBE at 2000 V. Gels were dried and exposed to a storage phosphor screen (Molecular Dynamics). Quantitation and data analysis
  • Io site and F rcf are the site and reference intensities, respectively, from a control lane to which no polyamide was added.
  • the ([L] tot , 2 W ) data points were fit to a general Hill equation (eq 2) by minimizing the difference between 2 and 2 m :
  • [L] tot is the total polyamide concentration
  • ⁇ is the equilibrium association constant
  • 2 min and 2 max are the experimentally determined site saturation values when the site is unoccupied or saturated, respectively.
  • the data were fit using a nonlinear least-squares fitting procedure with K ⁇ - 2 , ⁇ , and 2 min as the adjustable parameters.
  • association constants Four sets of data were used in determining each association constant.
  • the method for determining association constants used here involves the assumption that [L] ⁇ ⁇ r ⁇ , where [L] fre ⁇ is the concentration of polyamide free in solution (unbound). For very high association constants this assumption becomes invalid, resulting in underestimated association constants.
  • the DNA concentration is estimated to be "5 pM. As a consequence, apparent association constants greater than " 1010 M "1 should be regarded as lower limits.
  • a single 3 '-shifted cleavage pattern is observed at each 9 bp site indicating that the polyamide is bound in one orientation with the C-terminus at the 5' end of the 5'-AAAAAGACA-3' and 5' -ATATAG AC A-3' sequences.
  • the nine-ring polyamide ImPyPy- ⁇ -aminobutyric acid-ImPyPy- ⁇ - alanine-PyPyPy-G-Dp binds 5' -AAA AAG AC A-3' and 5'-ATATAGACA-3' with " 400-fold and " 100-fold higher affinity, respectively. Similar binding enhancements have recently been reported in a separate system. 8 Addition of a C-terminal PyPyPy subunit using a ⁇ -alanine linker is an effective strategy for increasing the DNA-binding affinity of hairpin polyamides that bind adjacent to an (A,T) 4 sequence.
  • Polyamide ImPyPy- ⁇ -aminobutyric acid-ImPyPy- ⁇ -alanine-PyPyPy-G-Dp binds several mismatch sites present on the 247 bp restriction fragment with high affinity.
  • the two highest affinity mismatch sites, 5'-GAATTCACT-3' (K a 4.5 x 10 9 M "1 ) and
  • the six-ring polyamide ImPyPy- ⁇ -aminobutyric acid-ImPyPy- ⁇ -alanine-Dp binds more strongly to the match site 5'-AGACA-3' over the single base-pair mismatch sites 5'-AT CA-3' and 5'-TTACA-3' by a factor of 10.
  • the sites 5'-AGTACA-3' and 5'-AGTATT-3' are for polyamide 1 "match” and "single base pair mismatch” sites, respectively, and for polyamide 2 "single base pair mismatch” and "match” sites, respectively ( Figure 2).
  • Polyamides 1 and 2 were synthesized by solid phase methods and purified by reversed phase HPLC 9 . The identity and purity of the polyamides was verified by H NMR, MALDI-TOF MS, and analytical HPLC.
  • MALDI-TOF MS 1, 1223.4 (1223.3 calculated for M+H); 2, 1222.3 (1222.3 calculated for M+H).
  • Equilibrium association constants for complexes of 1 and 2 with match and mismatch six base pair binding sites on a 3'- 32 P-labeled 229 bp restriction fragment were determined by quantitative DNase I footprint titration experiments 10 (Table I).
  • the reported association constants are the average values obtained from three DNase I footprint titration experiments. The standard deviation for each data set is indicated in parentheses. Assays were carried out in the presence of 10 mM Tris ⁇ HCl, 10 mM KC1, 10 mM MgCl 2> and 5 mM CaCl 2 at pH 7.0 and 22 °C. The six base-pair binding sites are in capital letters, with flanking sequences in lower-case letters.
  • Polyamide 1 binds its match site 5'-AGTACT-3' at 0.03 nM concentration and its single base pair mismatch site 5'-AGTATT-3' with nearly 100-fold lower affinity.
  • Polyamide 2 binds its designated match site 5'-AGTATT-3' at 0.3 nM concentration and its single base pair mismatch site 5'-AGTA£T-3' with nearly 10- fold lower affinity.
  • the specificity of 1 and 2 for their respective match sites results from very small structural changes.
  • Replacing a single nitrogen atom in 1 with C-H (as in 2) reduces the affinity of the polyamide*5'-AGTACT-3' complex by " 75-fold representing a free energy difference of " 2.5 kcal/mole.
  • replacing a C-H in 2 with N reduces the affinity of the polyamide*5'-AGTATT-3' complex " 10-fold, a loss in binding energy of "1.3 kcal/mol.
  • Plasmid pJT8 was prepared by hybridizing two 5'-phosphorylated complementary oligonucleotides, 5'-CCGGTTAGTATTTGGATGGGCCTGGTTAGTA- CTTGGATGGGAGACCGCCTGGGAATACCAGGTGTCGTATCTTAAG-3' and 5 - TCGACTCTTAAGATACGACACCTGGTATTCCCAGGCGGTCTCCCATCCAA- GTACTAACCAGGCCCATCCAAATACTAA-3' , and ligating the resulting duplex to the large pUC19 Aval/Sail restriction fragment.
  • Polyamides Polyamides were synthesized by solid phase methods. 12 The identity and purity of the polyamides was verified by l H NMR, matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS), and anlaytical HPLC. MALDI-TOF-MS: 1, 1223.4 (1223.3 calcd for M+H); 2, 1222.3 (1222.3 calcd for M+H); 3, 1223.1 (1223.3 calcd for M+H).
  • Fibroblasts from a Xenopus kidney derived cell line (kindly provided by Dr. P. Labhart, Scripps) were grown at ambient temperature in 25 cm 2 culture flasks in Dulbecco's modified Eagle medium containing 10% (v/v) fetal calf serum. Cells were passaged for a minimum of three days prior to the addiiton of polyamide to the culture medium. Incubations were continued for various times and nuclei were prepared by hypotonic lysis and used as templates for transcription as described.
  • the buffer components and labeled and unlabeled nucleoside triphosphates were as for the plasmid transcription reactions. Reactions were supplemented with 2 ⁇ L of RNA polymerase III (at approximately 50 ⁇ g/mL)isolated from Xenopus oocytes.
  • Xenopus kidney-derived fibroblasts were grown in the presence of increasing concentrations of polyamide 1 in the culture medium for various times. We found that concentrations of polyamide up to 1 ⁇ M were not toxic, as measured by cell density, if growth was limited to less than 72 hours.
  • Nuclei were prepared from cells by hypotonic lysis and equivalent amounts of the isolated nuclei from control and treated cells were used as templates for transcription with exogenous RNA polymerase III and labeled and unlabeled nucleoside triphosphates. This expermiment monitors the occupancy of class III genes with active transcription complexes. 19 5S RNA transcription can easily be assessed since the repetitive 5S genes give rise to a prominent band on a denaturing polyacrylamide gel. An autoradiogram was taken of the gel and the following observations made based on the observed autoradiogram.
  • polyamide 1 Concentrations of polyamide 1 as low as 100 nM have a pronounced and selective effect on 5S transcription. At higher polyamide concentration, a general decrease in the transcriptional activity of the nuclei is observed; however, at each concentration tested, the effects of the polyamide are much greater on 5S RNA transcrption than on tRNA transcription. Having established that nearly maximal inhibition of 5S transcription is achieved with 1 ⁇ M polyamide 1 , we monitored nuclear transcription after various times of cell growth in the presence of the polyamide. No inhibition is observed for zero time incubation with polyamide 1 at 1 ⁇ M concentration, indicating that disruption of transcription complexes does not occur during or after the isolation or work-up of cell nuclei. Statistically equivalent levels of 5S transcription were observed when the cells were exposed to polyamide 1 for 24, 48 or 72 hours.
  • the subject invention provides novel compounds, which are oligomers of organic cyclic groups, particularly azoles, where the compounds fit
  • compositions provide for substantial differentiation between the target sequence and single mismatch sequences. Normally, there will be at least a two-fold difference between the two sequences, more usually at least a five-fold difference, and preferentially at least a ten-fold difference or greater. In this way, one can insure that the target sequence will be primarily affected, with little effect on other sequences. Normally, the target sequence will be at least five nucleotides, usually at least six nucleotides, more usually at least eight nucleotides, and not more than about twenty nucleotides.
  • the subject compositions are shown to bind with high affinities to specific dsDNA sequences and with substantially lower affinities to single base mismatches. In this way, even in complex compositions of dsDNA, such as may be encountered in cellular compositions, there is substantial assurance that the target sequence will be affected and other sequences will be little affected, if at all. Furthermore, the subject compositions are capable of transport across a cellular membrane and through the cytosol to the nucleus. The subject compositions are capable of binding to chromosomal dsDNA involved with nucleosomes and inhibit transcription of genes which form complexes with the subject compositions. Single oligomers may be employed or combinations of oligomers to provide for the desired complex formation.
  • the subject compositions can accurately target the dsDNA and avoid the melting and competition between the natural strands and the labeled complementary strand, as is employed conventionally today.
  • the subject compositions may be used for cleavage of dsDNA at specific sites, so as to isolate target DNA, which may then be readily amplified using PCR.
  • By further modifying the subject compositions one may further expand their applications in their use for identifying sequences, cleaving specific sequences, investigating the role of genes, screening for the presence of sequences in cells, and inhibiting proliferation of cells.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des compositions permettant de former des complexes de manière intracellulaire entre un ADN à double brin et des oligomères d'hétérocycles, des acides aminés aliphatiques, plus particulièrement des acides oméga-aminés, et un groupe terminal polaire. En sélectionnant de manière adéquate des séquences cibles et une composition d'oligomères, on obtient des complexes avec de faibles constantes de dissociation. La formation de complexes peut être utilisée pour modifier le phénotype de cellules, soit procaryotes soit eucaryotes, à des fins de recherche et thérapeutiques.
PCT/US1997/012733 1997-05-08 1997-07-21 Formation de complexes entre un adn a double brin et un oligomere d'heterocycles WO1998050058A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97934244A EP0991417A1 (fr) 1997-05-08 1997-07-21 Formation de complexes entre un adn a double brin et un oligomere d'heterocycles
AU37347/97A AU747998B2 (en) 1997-05-08 1997-07-21 Complex formation between dsDNA and oligomer of heterocycles
CA002299455A CA2299455A1 (fr) 1997-05-08 1997-07-21 Formation de complexes entre un adn a double brin et un oligomere d'heterocycles
JP54801198A JP2002514219A (ja) 1997-05-08 1997-07-21 ｄｓＤＮＡと複素環オリゴマーとの間の複合体形成

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/853,525 US5998140A (en) 1996-07-31 1997-05-08 Complex formation between dsDNA and oligomer of cyclic heterocycles
US08/853,525 1997-05-08

Publications (1)

Publication Number Publication Date
WO1998050058A1 true WO1998050058A1 (fr) 1998-11-12

Family

ID=25316267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012733 WO1998050058A1 (fr) 1997-05-08 1997-07-21 Formation de complexes entre un adn a double brin et un oligomere d'heterocycles

Country Status (6)

Country Link
US (2) US5998140A (fr)
EP (1) EP0991417A1 (fr)
JP (1) JP2002514219A (fr)
AU (1) AU747998B2 (fr)
CA (1) CA2299455A1 (fr)
WO (1) WO1998050058A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559125B1 (en) 2000-01-28 2003-05-06 California Institute Of Technology Polyamide-alkylator conjugates and related products and method
WO2007103584A2 (fr) * 2006-03-09 2007-09-13 Nanovir, Llc Polyamides pour le traitement du virus du papillome humain
WO2007130616A3 (fr) * 2006-05-04 2008-01-17 Nanovir Llc Polyamides destinés au traitement du papillomavirus humain
US7935530B2 (en) 2006-11-29 2011-05-03 California Institute Of Technology Polyamides with tail structures capable of binding DNA
US8835480B2 (en) 2007-04-23 2014-09-16 California Institute Of Technology Inhibitors for steroid response elements and related methods
US9133228B2 (en) 2011-10-10 2015-09-15 Nanovir Llc Guanidinyl-substituted polyamides useful for treating human papilloma virus
US9290551B2 (en) 2012-01-25 2016-03-22 Nanovir Llc Compounds for treating papilloma virus infection
US9630950B2 (en) 2007-04-23 2017-04-25 California Institute Of Technology Inhibitors for steroid response elements and RNA polymerase II and related methods
US9982020B2 (en) 2011-10-10 2018-05-29 Nanovir Llc Antiviral compounds and methods for treating infections caused by double-stranded DNA viruses
US10307401B2 (en) 2016-08-29 2019-06-04 California Institute Of Technology Compositions and methods for treatment of prostate cancer
CN116120238A (zh) * 2023-03-01 2023-05-16 山东梅奥华卫科技有限公司 一种咪唑衍生物的制备方法

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264427B1 (fr) 1997-01-31 2017-05-03 Xy, Llc Dispositif optique avec réflecteur focalisant pour faire converger la radiation sur un débit de particule, et procédé d'analyse associé
US6149867A (en) 1997-12-31 2000-11-21 Xy, Inc. Sheath fluids and collection systems for sex-specific cytometer sorting of sperm
JP3649617B2 (ja) * 1999-03-26 2005-05-18 独立行政法人科学技術振興機構 ２本鎖ｄｎａを切断できる化合物及びその使用方法
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US20040248150A1 (en) * 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US20030235832A1 (en) * 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US7001725B2 (en) 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US7037654B2 (en) 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US6692914B1 (en) 1999-07-02 2004-02-17 Symyx Technologies, Inc. Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto
US7208265B1 (en) 1999-11-24 2007-04-24 Xy, Inc. Method of cryopreserving selected sperm cells
US6610489B2 (en) 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
WO2001083819A2 (fr) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Procédés d'élaboration de molécules régulatrices exogènes
US7217509B2 (en) * 2000-04-28 2007-05-15 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
US20030207300A1 (en) * 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US7160735B2 (en) * 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
EP1416972B1 (fr) * 2000-11-09 2012-02-08 Cold Spring Harbor Laboratory Molecules chimeres servant a moduler l'expression d'un gene
US7713687B2 (en) 2000-11-29 2010-05-11 Xy, Inc. System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations
BRPI0115792B1 (pt) 2000-11-29 2020-05-05 Colorado State Univ sistema para separação de espermatozóides congelados/descongelados em populações portadoras de cromossomo-x e portadoras de cromossomo-y
EP1215199A1 (fr) * 2000-12-08 2002-06-19 Sony International (Europe) GmbH Linker molécules pour la métallisation sélective des acides nucléiques et de leurs utilisations
US7205161B2 (en) * 2001-01-10 2007-04-17 Symyx Technologies, Inc. Polymer brushes for immobilizing molecules to a surface or substrate having improved stability
DE10104025B4 (de) * 2001-01-31 2008-07-10 Qiagen North American Holdings, Inc. Verfahren zur Aufreinigung und anschließenden Amplifikation von Doppelstrang-DNA
EP2332896A3 (fr) * 2001-03-19 2012-09-26 President and Fellows of Harvard College Evolution d'une nouvelle fonction moléculaire
US7122626B2 (en) * 2001-04-26 2006-10-17 Genesoft Pharmceuticals, Inc. Halogen-substitued thienyl compounds
CZ20033143A3 (en) 2001-05-21 2004-04-14 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
HUP0501021A3 (en) 2001-05-21 2006-06-28 Aclara Biosciences Inc Mountai Methods and compositions for analyzing proteins
US7358052B2 (en) * 2001-05-26 2008-04-15 Monogram Biosciences, Inc. Catalytic amplification of multiplexed assay signals
US6777425B2 (en) * 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
JP2005505508A (ja) 2001-06-13 2005-02-24 ジーンソフト ファーマシューティカルズ インコーポレイテッド 抗感染活性を有するベンゾチオフェン化合物
AU2002312371A1 (en) * 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
US20030236198A1 (en) * 2001-06-13 2003-12-25 Genesoft, Inc. Antipathogenic benzamide compounds
DE60221986D1 (de) 2001-06-20 2007-10-04 Nuevolution As Eine methode zur synthese von matrizenabhängigen molekülen
AU2002356916A1 (en) * 2001-11-07 2003-05-19 Pharmacia Corporation Polyamide modulators of cox2 transcription
BR0213989A (pt) * 2001-11-07 2005-03-01 Pharmacia Corp Métodos para promover a absorção e acúmulo nuclear de poliamidas em células eucarióticas
JP4595067B2 (ja) 2002-08-01 2010-12-08 エックスワイ，エルエルシー 低圧精子細胞分離システム
US8486618B2 (en) 2002-08-01 2013-07-16 Xy, Llc Heterogeneous inseminate system
US7498349B2 (en) 2002-08-02 2009-03-03 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
CA2534394C (fr) 2002-08-15 2013-01-08 Xy, Inc. Cytometre a flux haute resolution
JP4657919B2 (ja) * 2002-08-19 2011-03-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 進化する新しい分子機能
US7169548B2 (en) 2002-09-13 2007-01-30 Xy, Inc. Sperm cell processing and preservation systems
CA2503119A1 (fr) * 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Composes biaryle anti-infectieux
WO2004046387A1 (fr) * 2002-11-15 2004-06-03 Sangamo Biosciences, Inc. Methodes et compositions destinees a l'analyse de sequences regulatrices
CA2508769A1 (fr) 2002-12-10 2004-06-24 Oscient Pharmaceuticals Corporation Composes antibacteriens possedant un motif (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide)
US8017323B2 (en) 2003-03-26 2011-09-13 President And Fellows Of Harvard College Free reactant use in nucleic acid-templated synthesis
ES2918578T3 (es) 2003-03-28 2022-07-19 Inguran Llc Aparato y métodos para proporcionar esperma animal clasificado por sexo
CA2531869A1 (fr) * 2003-04-30 2004-11-18 Pharmacia Corporation Composes comportant une fraction bicyclique fusionnee qui se lie au petit sillon d'adn double brin
NZ544103A (en) 2003-05-15 2010-10-29 Xy Llc Efficient haploid cell sorting for flow cytometer systems
WO2005033282A2 (fr) * 2003-10-01 2005-04-14 Pharmacia & Upjohn Company Llc Compositions polyamide et methodes therapeutiques pour traiter un papillomavirus humain
CA2543830A1 (fr) * 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detection d'anticorps anti-therapeutique humain
US20050123932A1 (en) * 2003-12-09 2005-06-09 Mekbib Astatke Nucleic acid-chelating agent conjugates
US20060174364A1 (en) * 2004-03-01 2006-08-03 Avigenics, Inc. Artificial chromosomes and transchromosomic avians
NZ550197A (en) * 2004-03-29 2009-10-30 Inguran Llc Use of a composition which regulates oxidation/reduction reactions intracellularly and/or extracellularly in a staining or sorting process of spermatozoa
CA2561519C (fr) * 2004-03-29 2017-08-22 Monsanto Technology Llc Suspensions de sperme pour insemination
WO2005112924A2 (fr) * 2004-04-27 2005-12-01 California Institute Of Technology Technique de traitement du cancer par inhibition de l'expression du gene histone
US20060025429A1 (en) * 2004-06-07 2006-02-02 Dervan Peter B Composition and methods for inhibiting expression of hypoxia-inducible genes
CA2574499C (fr) 2004-07-22 2016-11-29 Monsanto Technology Llc Procede pour enrichir une population de spermatozoides
WO2007011722A2 (fr) 2005-07-15 2007-01-25 President And Fellows Of Harvard College Systeme de decouverte de reaction
WO2010028288A2 (fr) 2008-09-05 2010-03-11 Aueon, Inc. Procédés pour la stratification et l’annotation des options de traitement médicamenteux contre le cancer
EP2354242A1 (fr) 2010-02-03 2011-08-10 Epiontis GmbH Analyse pour déterminer le type et/ou le statut d'une cellule en fonction du motif épigénétique et la structure chromatique
NZ608313A (en) 2010-09-24 2013-12-20 Univ Leland Stanford Junior Direct capture, amplification and sequencing of target dna using immobilized primers
AU2015357516A1 (en) 2014-12-05 2017-06-15 Inguran, Llc Cell processing using magnetic particles
WO2018047148A1 (fr) 2016-09-12 2018-03-15 Novartis Ag Composés pour inhibition du miarn
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
WO2020191064A1 (fr) 2019-03-19 2020-09-24 Inguran, Llc Procédé pour des populations de cellules spermatiques améliorées
WO2021160802A1 (fr) 2020-02-13 2021-08-19 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Procédé pour une annotation automatique de tissu fonctionnelle, basée sur la sémantique, de caractéristiques histologiques et cellulaires afin d'identifier des caractéristiques moléculaires dans des échantillons de tissu

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8612218D0 (en) * 1986-05-20 1986-06-25 Erba Farmitalia Site specific alkylating agents
GB8906709D0 (en) * 1989-03-23 1989-05-10 Creighton Andrew M Acryloyl substituted pyrrole derivatives
CA2005039A1 (fr) * 1989-12-08 1991-06-08 Randell L. Mills Produit pharmaceutique et appareil pour l'obtention d'un diagnostic par necrose selective de tissus
IT1243389B (it) * 1990-11-22 1994-06-10 Menarini Farma Ind Derivati poliaminopirrolcarbossiamidici, processi di preparazione e composizioni farmaceutiche che li contengono.
AU1224392A (en) * 1991-02-06 1992-09-07 Synphar Laboratories, Inc. Oligopeptide antiretroviral agents
IT1247878B (it) * 1991-02-15 1995-01-05 Menarini Farma Ind Derivati poli-4-aminopirrol-2-carbossiamidici,processi di preparazione e composizioni farmaceutiche che li contengono
US5578444A (en) * 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
CA2112130C (fr) * 1991-06-27 1996-08-06 Cynthia A. Edwards Analyse de detection de molecules de fixation de l'adn
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
GB2261661A (en) * 1991-11-21 1993-05-26 Erba Carlo Spa Derivatives of poly-4-amino-2-carboxy-1-methyl pyrroles
US5273991A (en) * 1992-07-29 1993-12-28 Research Corporation Technologies, Inc. Imidazole-containing compositions and methods of use thereof analogs of distamycin
IT1271456B (it) * 1993-03-01 1997-05-28 Menarini Farma Ind Composti pirrol-amidinici, e loro sali farmaceuticamente accettabili, processi di preparazione e composizioni farmaceutiche che li contengono
IT1263089B (it) * 1993-04-26 1996-07-24 Menarini Farma Ind Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
WO1995004732A1 (fr) * 1993-08-06 1995-02-16 Synphar Laboratories, Inc. Agents antiretroviraux oligopeptidiques
US5698674A (en) * 1994-04-13 1997-12-16 The Regents Of The University Of California Triheterocyclic peptides capable of binding the minor and major grooves of DNA
GB9416005D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Peptidic compounds analogous to distamycin a and process for their preparation
GB9514993D0 (en) * 1995-07-21 1995-09-20 Pharmacia Spa Site specific phenyl nitrogen mustards
IL125441A0 (en) * 1996-02-01 1999-03-12 Merck Frosst Canada Inc Novel diphenyl stilbenes and pharmaceutical compositions thereof for treatment of cox-2 mediated diseases
IT1282586B1 (it) 1996-02-08 1998-03-31 Chemical And Biolog Ind Composizioni farmaceutiche per il trattamento biologico delle infezioni dovute a ceppi di enterococcus faecium resistenti agli
US6090947A (en) * 1996-02-26 2000-07-18 California Institute Of Technology Method for the synthesis of pyrrole and imidazole carboxamides on a solid support

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHO et al., "Cyclic Polyamides for Recognition in the Minor Groove of DNA", PROC. NATL. ACAD SCI. USA, October 1995, Vol. 92, pages 10389-10392. *
KELLY et al., "Binding Site Size Limit of the 2:1 Pyrrole-Imidazole Polyamide-DNA Motif", PROC. NATL. ACAD. SCI. USA, July 1996, Vol. 93, pages 6981-6985. *
MRKISCH et al., "Design of a Covalent Peptide Heterodimer for Sequence Specific Recognition in the Minor Groove of Double-Helical DNA", J. AM. CHEM. SOC., 1994, Vol. 116, pages 3663-3664. *
PILCH et al., "Binding of a Hairpin Polyamide in the Minor Groove of DNA: Sequence-Specific Enthalpic Discrimination", PROC. NATL. ACAD. SCI. USA, August 1996, Vol. 93, pages 8306-8311. *
TRAUGER et al., "Recognition of DNA by Designed Ligands at Subnanomolar Concentrations", NATURE, 08 August 1996, Vol. 382, pages 559-561. *
WADE et al., "Design of Peptides that Bind in the Minor Groove of DNA at 5'-(A,T)G(A,T)C(A,T)-3' Sequences by a Dimeric Side-by-Side Motif", J. AM. CHEM. SOC., 1992, Vol. 114, pages 8783-8794. *
WHITE et al., "Effects of the A-T/T-A Degeneracy of Pyrrole-Imidazole Polyamide Recognition in the Minor Groove of DNA", BIOCHEMISTRY, 1996, Vol. 35, No. 38, pages 12532-12537. *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559125B1 (en) 2000-01-28 2003-05-06 California Institute Of Technology Polyamide-alkylator conjugates and related products and method
WO2007103584A2 (fr) * 2006-03-09 2007-09-13 Nanovir, Llc Polyamides pour le traitement du virus du papillome humain
WO2007103584A3 (fr) * 2006-03-09 2007-11-08 Nanovir Llc Polyamides pour le traitement du virus du papillome humain
US9333232B2 (en) 2006-05-04 2016-05-10 Nanovir Llc Methods for treating papilloma virus infection
WO2007130616A3 (fr) * 2006-05-04 2008-01-17 Nanovir Llc Polyamides destinés au traitement du papillomavirus humain
US7589171B2 (en) 2006-05-04 2009-09-15 Nanovir, Llc Polyamides for treating human papilloma virus
US8119677B2 (en) 2006-05-04 2012-02-21 Nanovir, Llc Polyamides containing amino butyric acid-based building blocks
US7935530B2 (en) 2006-11-29 2011-05-03 California Institute Of Technology Polyamides with tail structures capable of binding DNA
US8835480B2 (en) 2007-04-23 2014-09-16 California Institute Of Technology Inhibitors for steroid response elements and related methods
US9630950B2 (en) 2007-04-23 2017-04-25 California Institute Of Technology Inhibitors for steroid response elements and RNA polymerase II and related methods
US9133228B2 (en) 2011-10-10 2015-09-15 Nanovir Llc Guanidinyl-substituted polyamides useful for treating human papilloma virus
US9982020B2 (en) 2011-10-10 2018-05-29 Nanovir Llc Antiviral compounds and methods for treating infections caused by double-stranded DNA viruses
US9290551B2 (en) 2012-01-25 2016-03-22 Nanovir Llc Compounds for treating papilloma virus infection
US10307401B2 (en) 2016-08-29 2019-06-04 California Institute Of Technology Compositions and methods for treatment of prostate cancer
CN116120238A (zh) * 2023-03-01 2023-05-16 山东梅奥华卫科技有限公司 一种咪唑衍生物的制备方法
CN116120238B (zh) * 2023-03-01 2023-09-22 山东梅奥华卫科技有限公司 一种咪唑衍生物的制备方法

Also Published As

Publication number Publication date
US6303312B1 (en) 2001-10-16
CA2299455A1 (fr) 1998-11-12
US5998140A (en) 1999-12-07
EP0991417A1 (fr) 2000-04-12
AU3734797A (en) 1998-11-27
AU747998B2 (en) 2002-05-30
JP2002514219A (ja) 2002-05-14

Similar Documents

Publication Publication Date Title
US5998140A (en) Complex formation between dsDNA and oligomer of cyclic heterocycles
US6143901A (en) Complex formation between dsDNA and pyrrole imidazole polyamides
US6635417B1 (en) Complex formation between DSDNA and oligomer of cyclic heterocycles
Belitsky et al. Solid-phase synthesis of DNA binding polyamides on oxime resin
JP3231045B2 (ja) 固体支持体上でのポリピロール及びポリイミダゾールカルボキサミドの合成方法
AU749953B2 (en) Inhibition of gene transcription by polyamide DNA-binding ligands
CN1260006A (zh) 双链dna和杂环低聚物之间复合物的形成
EP0986539A1 (fr) Derives de polyamides pyrrole-imidazole liant l'adn
EP1599474B1 (fr) Composés oligomères hétérocycliques pour reconnaissance d'ADN
US7049061B1 (en) Stereochemical control of the DNA binding affinity, sequence specificity, and orientation-preference of chiral hairpin polyamides in the minor groove
MX2010012320A (es) Nuevos conjugados antitumorales de doble orientacion.
US6559125B1 (en) Polyamide-alkylator conjugates and related products and method
US6673940B1 (en) Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
JP2006502219A (ja) 化合物、組成物および方法
CA2531869A1 (fr) Composes comportant une fraction bicyclique fusionnee qui se lie au petit sillon d'adn double brin
EP1144414B1 (fr) Compositions et methodes concernant des composes cycliques subissant des interactions specifiques de paires de bases nucleotidiques avec des acides nucleiques bicatenaires
US7728000B2 (en) Substituted quinolines for the treatment of cancer
WO2019230669A1 (fr) Composition pharmaceutique ciblant une séquence de liaison au runx, et inhibiteur du runx
CA2597903A1 (fr) Lipides cationiques pour la transfection d'acides nucleiques
WO2002034295A1 (fr) Composes regulateurs de synthese
CN116925084A (zh) 对肿瘤过表达的细胞周期调节蛋白wee1有双重抑制作用的化合物
CN116836179A (zh) 具有肿瘤靶向的溴结构域蛋白brd4抑制剂

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2299455

Country of ref document: CA

Ref country code: CA

Ref document number: 2299455

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997934244

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997934244

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997934244

Country of ref document: EP